IP finance

"Where money issues meet IP rights". This weblog looks at financial issues for intellectual property rights: securitisation and collateral, IP valuation for acquisition and balance sheet purposes, tax and R&D breaks, film and product finance, calculating quantum of damages--anything that happens where IP meets money.

Showing posts with label NIH. Show all posts
Showing posts with label NIH. Show all posts
Wednesday, 12 June 2024

Was the U.S. National Institutes of Health conflicted during the COVID-19 pandemic period?

›
Jon Cohen at Science has an interesting and informative article titled, “Accusers’ bad math: NIH researchers didn’t pocket $710 million inro...
Monday, 22 January 2024

U.S. GAO Report on Tracking U.S. Government Funding to Foreign Entities

›
The U.S. Government Accountability Office released a report on January 11, 2024, which studies federal funding provided to foreign entities ...
Tuesday, 23 May 2023

U.S. Government Accountability Office Report on Unwanted University Tech Transfer Risk

›
The U.S. Government Accountability Office has released a report titled, “CHINA Efforts Underway to Address Technology Transfer Risk at U.S. ...
Monday, 26 April 2021

Balancing Security Concerning University Research and Anti-Asian Sentiment in the United States: U.S. Senate Hearings

›
On April 22, 2021, the U.S. Senate Committee on Health, Education, Labor and Pensions held hearings on “Protecting U.S. Biomedical Research:...
Friday, 18 October 2019

Improving the Allocation of Resources: Artificial Intelligence to Predict Future Clinical Success of Basic Research

›
In a new paper published on October 10, 2019 titled, “Predicting Translational Progress in Biomedical Research,” authors B. Ian Hutchins,...
›
Home
View web version
Powered by Blogger.